N-methyl-d-aspartate (nmda) receptor blockers for the prevention of atherosclerosis
CA 2288149 A1 · Owner: Rosenquist, Thomas H. · Inventors: Monaghan, Daniel T.; Gadson, Preston F.; Rosenquist, Thomas H.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to the novel finding that homocysteine affects the initiation and/or progress of atherosclerosis via a receptor-mediated growth factor effect on vascular smooth muscle cells. This growth factor effect can be inhibited by N-methyl-D-aspartate antagonists via a unique receptor that is in the NMDA receptor family. Through the use of cloning and other procedures, this homocysteine receptor can be characterized in order to develop novel pharmacologic strategies that address the receptor for the prevention and treatment of atherosclerosis.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 31, 1997. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 31, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 31, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.